myLaminin Perspectives

A practical guide to building a CTMS business case focusing on ROI, operational efficiency, visibility, accountability, compliance, and risk reduction. Learn how clinical research organizations, academic medical centers, universities, CROs, and research institutions can quantify the cost of manual trial management and evaluate how a modern CTMS can improve study start-up, site performance, audit readiness, and research operations nationwide.

Clinical trial start-up delays continue to impact site activation, budgets, and timelines due to fragmented workflows across feasibility, contracting, IRB/REB approvals, training, and system readiness. This article explains how CTMS platforms, integrated research systems, and AI-driven automation reduce inefficiencies by centralizing processes, improving visibility, and accelerating trial activation across global clinical research environments.

CROs have evolved into essential partners in clinical trials, offering scalability, expertise, and global reach amid rising complexity. However, fragmented systems, blurred oversight, and data silos create risk. The future lies in integrated platforms like myLaminin that connect sponsors, CROs, and sites, improving transparency, governance, and execution across decentralized research ecosystems.